These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

54 related articles for article (PubMed ID: 3214450)

  • 1. Pharmacokinetics of aspoxicillin in subjects with normal and impaired renal function.
    Geyer J; Höffler D; Koeppe P
    Arzneimittelforschung; 1988 Nov; 38(11):1635-9. PubMed ID: 3214450
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacokinetics of ceftazidime in normal and impaired renal function.
    Höffler D; Koeppe P; Williams KJ
    Arzneimittelforschung; 1984; 34(1):72-6. PubMed ID: 6367755
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics of amoxicillin in subjects with normal and impaired renal function.
    Arancibia A; Drouguett MT; Fuentes G; González G; González C; Thambo S; Palombo G
    Int J Clin Pharmacol Ther Toxicol; 1982 Oct; 20(10):447-53. PubMed ID: 7141752
    [TBL] [Abstract][Full Text] [Related]  

  • 4. On the pharmacokinetics of latamoxef in normal and impaired renal function.
    Höffler D; Koeppe P; Moecke D
    Arzneimittelforschung; 1984; 34(3):317-20. PubMed ID: 6539614
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmacokinetics and pharmacodynamics of lobaplatin (D-19466) in patients with advanced solid tumors, including patients with impaired renal of liver function.
    Welink J; Boven E; Vermorken JB; Gall HE; van der Vijgh WJ
    Clin Cancer Res; 1999 Sep; 5(9):2349-58. PubMed ID: 10499604
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of lenalidomide in subjects with various degrees of renal impairment and in subjects on hemodialysis.
    Chen N; Lau H; Kong L; Kumar G; Zeldis JB; Knight R; Laskin OL
    J Clin Pharmacol; 2007 Dec; 47(12):1466-75. PubMed ID: 17954615
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bromfenac disposition in patients with impaired kidney function.
    Ermer JC; Boni JP; Cevallos WH; DeCleene S; Burghart P; Rudnick MR; Fruncillo RJ; Berns JS; Cohen RM
    Clin Pharmacol Ther; 1997 Mar; 61(3):312-8. PubMed ID: 9084456
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacokinetics of Cefmenoxime in normal and impaired renal function.
    Höffler D; Koeppe P
    Arzneimittelforschung; 1983; 33(2):269-72. PubMed ID: 6303362
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of anakinra in subjects with different levels of renal function.
    Yang BB; Baughman S; Sullivan JT
    Clin Pharmacol Ther; 2003 Jul; 74(1):85-94. PubMed ID: 12844139
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics in renally impaired subjects of NXY-059, a nitrone-based, free-radical trapping agent developed for the treatment of acute stroke.
    Strid S; Borgå O; Edenius C; Jostell KG; Odergren T; Weil A
    Eur J Clin Pharmacol; 2002 Sep; 58(6):409-15. PubMed ID: 12242600
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparison of zopiclone pharmacokinetics in patients with impaired renal function and normal subjects. Effect of hemodialysis.
    Marc-Aurele J; Caille G; Bourgoin J
    Sleep; 1987; 10 Suppl 1():22-6. PubMed ID: 3438644
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Cefamandol: pharmacokinetics with normal and impaired renal function (author's transl)].
    Höffler D; Moecke D; Sassmann M
    Dtsch Med Wochenschr; 1978 Aug; 103(34):1334-8. PubMed ID: 679835
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of norfloxacin in chronic renal failure.
    Arrigo G; Cavaliere G; D'Amico G; Passarella E; Broccali G
    Int J Clin Pharmacol Ther Toxicol; 1985 Sep; 23(9):491-6. PubMed ID: 4055162
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Pharmacokinetics of alpha-lipoic acid in subjects with severe kidney damage and end-stage renal disease.
    Teichert J; Tuemmers T; Achenbach H; Preiss C; Hermann R; Ruus P; Preiss R
    J Clin Pharmacol; 2005 Mar; 45(3):313-28. PubMed ID: 15703366
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Pharmacokinetics of intramuscular mezlocillin in patients with normal and impaired renal function (author's transl)].
    Brogard JM; Comte F; Kopferschmitt J; Dorner M; Lavillaureix
    Nouv Presse Med; 1982 Feb; 11(5 Pt 2):340-6. PubMed ID: 6460973
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Pharmacokinetics of cicletanine in patients with impaired renal function.
    Jungers P
    Drugs Exp Clin Res; 1988; 14(2-3):189-94. PubMed ID: 3416723
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pharmacokinetics of ibopamine in patients with renal impairment.
    Salvadeo A; Villa G; Bovio G; Pocchiari F; Pataccini R; Longo A; Ventresca GP
    Int J Clin Pharmacol Ther Toxicol; 1988 Feb; 26(2):98-104. PubMed ID: 3410592
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics of nitrendipine in patients with renal failure: comparison to normal subjects.
    Aronoff GR
    J Cardiovasc Pharmacol; 1984; 6 Suppl 7():S974-6. PubMed ID: 6085387
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of renal function on plasma levels and urinary excretion of acebutolol and its main N-acetyl metabolite.
    Kirch W; Köhler H; Berggren G; Braun W
    Clin Nephrol; 1982 Aug; 18(2):88-94. PubMed ID: 7140021
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pharmacokinetics of nicotine in kidney failure.
    Molander L; Hansson A; Lunell E; Alainentalo L; Hoffmann M; Larsson R
    Clin Pharmacol Ther; 2000 Sep; 68(3):250-60. PubMed ID: 11014406
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.